Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV.
Eur J Clin Microbiol Infect Dis
; 39(6): 1021-1026, 2020 Jun.
Article
in English
| MEDLINE | ID: covidwho-1718753
ABSTRACT
Since December 2019, the infection of the new coronavirus (COVID-19) caused an outbreak of new coronavirus pneumonia in Wuhan, China, and caused great public concern. Both COVID-19 and SARS-CoV belong to the coronavirus family and both invade target cells through ACE2. An in-depth understanding of ACE2 and a series of physiological and physiological changes caused by the virus invading the human body may help to discover and explain the corresponding clinical phenomena and then deal with them timely. In addition, ACE2 is a potential therapeutic target. This article will summarize the role of ACE2 in multiple organ damage caused by COVID-19 and SARS-CoV, targeted blocking drugs against ACE2, and drugs that inhibit inflammation in order to provide the basis for subsequent related research, diagnosis and treatment, and drug development.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia
/
Pneumonia, Viral
/
Angiotensin-Converting Enzyme Inhibitors
/
Coronavirus Infections
/
Peptidyl-Dipeptidase A
/
Severe Acute Respiratory Syndrome
/
Severe acute respiratory syndrome-related coronavirus
/
Pandemics
/
Betacoronavirus
Type of study:
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Eur J Clin Microbiol Infect Dis
Journal subject:
Communicable Diseases
/
Microbiology
Year:
2020
Document Type:
Article
Affiliation country:
S10096-020-03883-y
Similar
MEDLINE
...
LILACS
LIS